Annette Clancy has been appointed Chair of the Board of Directors of Lysogene. Ms. Clancy was previously a non-executive member of company's board. Ms. Clancy's prior roles within the healthcare, life sciences and biotechnology sectors span research and development as well as M&A, partnerships and funding.

She will now bring her experience in business development, clinical research, and commercialization of innovative drug therapies to Lysogene. She will be based in the U.K. In addition to her role as Chair of company's Board of Directors, Ms. Clancy will maintain her role as a non-executive board member of other private and public biotechnology companies. She currently chairs the Board at Genable Technologies Ltd. (Ireland) and ObsEva Ltd. (Switzerland), and she is a non-executive Director on the board of SOBI Inc. (Sweden).